These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9681299)

  • 1. Soluble interleukin-2 receptors (sIL-2R) in ovarian cancer patients: changes in sIL-2R after surgery as a prognostic factor?
    Gebauer G; Rieger M; Jäger W; Lang N
    Int J Biol Markers; 1998; 13(1):45-7. PubMed ID: 9681299
    [No Abstract]   [Full Text] [Related]  

  • 2. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
    Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implication of serum sIL-2R levels in ovarian cancer.
    Wang S; Cai G; Lu Y
    J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
    Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
    Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
    Naumnik W; Chyczewska E
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
    Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
    Lissoni P; Rizzo V; Barni S; Rescaldani R; Rovelli F; Biondi A; Archili C; Frigerio F; Tancini G
    Int J Biol Markers; 1989; 4(3):170-3. PubMed ID: 2614085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
    Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
    Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
    Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
    Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis.
    Chen X; Li Y; Ding X; Zou J; Shen B; Liu Z; Lv W; Cao X; Xiang F
    Ren Fail; 2020 Nov; 42(1):419-427. PubMed ID: 32401100
    [No Abstract]   [Full Text] [Related]  

  • 15. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
    Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
    Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
    Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
    Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of sIL-2R levels in B-cell lymphomas.
    Yoshida N; Oda M; Kuroda Y; Katayama Y; Okikawa Y; Masunari T; Fujiwara M; Nishisaka T; Sasaki N; Sadahira Y; Mihara K; Asaoku H; Matsui H; Seto M; Kimura A; Arihiro K; Sakai A
    PLoS One; 2013; 8(11):e78730. PubMed ID: 24236041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
    De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
    Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
    Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.